Composition for treating cardiovascular and cerebrovascular diseases, and preparation and inspection method thereof

A technology for cardiovascular and cerebrovascular diseases and testing methods, applied in cardiovascular system diseases, drug combinations, active ingredients of hydroxyl compounds, etc., can solve the problems of low bioavailability, adverse clinical efficacy, etc. Quantity, the effect of solving physical and mental pain

Inactive Publication Date: 2017-05-31
合肥七星医药科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Vitexin is flavonoid C glycoside, oral preparation, its bioavailability is low, which is not conducive to the clinical efficacy of this product, so we make vitexin and mannitol into a freeze-dried powder composition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating cardiovascular and cerebrovascular diseases, and preparation and inspection method thereof
  • Composition for treating cardiovascular and cerebrovascular diseases, and preparation and inspection method thereof
  • Composition for treating cardiovascular and cerebrovascular diseases, and preparation and inspection method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1: Preparation of Vitexin Mannitol for Injection

[0028] a. Weigh 30g vitexin and 180g mannitol and mix them evenly, add 600ml water for injection, stir evenly, then add 1500ml 0.1mol / L sodium hydroxide solution, stir to dissolve, then adjust to 1mol / L hydrochloric acid solution When the pH is around 8.5, add water for injection to 3000ml, add 0.05% activated carbon for needles, stir for 10 minutes, decompress and coarsely filter with a microporous titanium filter, decarbonize, check the content and pH, and then pass through a 0.22μm microporous filter After membrane terminal filtration, it was divided into 10ml vials with 3ml in each bottle, and then freeze-dried at low temperature.

[0029] b. Pre-freezing: Put the subpackaged medicines on the inner shelf of the freeze-drying box and start to pre-freeze to +25°C ~ -40°C for 2 hours; -40°C for 3 hours.

[0030] c. Sublimation drying: Lower the temperature of the condenser to below -45°C, start the vacuum p...

Embodiment 2

[0032] Embodiment 2: the inspection of vitexin mannitol for injection

[0033] (1) Take 14.0 mg of this product, add ethanol to make a solution containing 20 μg vitexin per 1 ml, as the test solution; take vitexin reference substance to make the reference solution in the same way. Test according to thin-layer chromatography (Appendix VIB of Chinese Pharmacopoeia 2010 Edition), absorb each 5 μ l of the test solution and the reference solution, respectively spot on the same polyamide membrane, use 36% acetic acid as the developing agent, develop, take out, Dry it in the air, spray it with 1% aluminum chloride solution, blow it dry with hot air, and inspect it under an ultraviolet lamp (365nm). In the chromatogram of the test product, on the position corresponding to the chromatogram of the reference product, fluorescent spots of the same color appear;

[0034] (2) Take 7.0 mg of this product, add ethanol to make a solution containing 10 μg of the main drug per 1 ml, and measure ...

Embodiment 3

[0040] Embodiment 3: Clinical application of vitexin mannitol for injection

[0041] Intravenous infusion, 1 bottle at a time, once a day; use after dissolving with 150ml of normal saline. The specific usage is to take 3-5ml of water for injection with a sterile injection needle, inject it into a vial containing a combination of vitexin and mannitol, shake well to dissolve, then use a sterile needle to absorb and inject 150ml of normal saline, shake well Afterwards, use the method of intravenous infusion to drip into the patient's vein.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a composition for treating cardiovascular and cerebrovascular diseases, and a preparation and inspection method thereof. The composition is prepared from vitexin and mannitol according to a weight ratio of 1 to (6 to 10) on the basis of dry weight. The mixed composition of the vitexin and the mannitol for treating the cardiovascular and cerebrovascular diseases has the advantages that in the aspects of resisting the myocardial ischemia, reducing the myocardial oxygen consumption, improving the haemodynamics, resisting the cerebral ischemia and the like, the curative effect is exact and obvious; the action speed is high; the quality is stable and controllable; no adverse reaction exists; no toxic or side effects exist; the cost is low; the requirements of broad masses of patients can be better met; the mind and body pain of the patients is relieved; good social benefits and economic benefits are realized.

Description

[0001] This application is a divisional application submitted on December 21, 2012, with application number 201210559202.0, and the title of the invention is "composition for treating cardiovascular and cerebrovascular diseases and its preparation and testing method". technical field [0002] The present invention relates to a composition for treating cardiovascular disease and cerebrovascular disease and its preparation and testing method, in particular to a mixed composition comprising vitexin and mannitol, which has anti-myocardial ischemia, It has remarkable effects in reducing myocardial oxygen consumption, improving hemodynamics and resisting cerebral ischemia. Background technique [0003] According to the latest World Health Report, the incidence and mortality of coronary heart disease have shown a rapid growth trend in recent years. According to statistics, 1 out of every 3 deaths due to disease worldwide is due to cardiovascular disease. It is estimated that by 2020...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/047A61K9/19A61P9/00A61P9/10G01N30/90G01N30/02G01N21/33G01N21/78
Inventor 邵旭何万龙牛海军李晓亮
Owner 合肥七星医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap